514 related articles for article (PubMed ID: 27310254)
21. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O; Hauser IA; Bartels M; Wolf G; Wolters H; Nitschke M;
Transplantation; 2012 Jan; 93(1):61-8. PubMed ID: 22094954
[TBL] [Abstract][Full Text] [Related]
22. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease.
Taber DJ; Ashcraft E; Baillie GM; Berkman S; Rogers J; Baliga PK; Rajagopalan PR; Lin A; Emovon O; Afzal F; Chavin KD
Transpl Infect Dis; 2004 Sep; 6(3):101-9. PubMed ID: 15569225
[TBL] [Abstract][Full Text] [Related]
23. Valganciclovir (VGCV) followed by cytomegalovirus (CMV) hyperimmune globulin compared to VGCV for 200 days in abdominal organ transplant recipients at high risk for CMV infection: A prospective, randomized pilot study.
Fleming JN; Taber DJ; Weimert NA; Nadig S; McGillicuddy JW; Bratton CF; Baliga PK; Chavin KD
Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28921781
[TBL] [Abstract][Full Text] [Related]
24. Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease.
Halleck F; Khadzhynov D; Schrezenmeier E; Lehner L; Budde K; Staeck O
Transplant Proc; 2017 Dec; 49(10):2280-2284. PubMed ID: 29198661
[TBL] [Abstract][Full Text] [Related]
25. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial.
Palmer SM; Limaye AP; Banks M; Gallup D; Chapman J; Lawrence EC; Dunitz J; Milstone A; Reynolds J; Yung GL; Chan KM; Aris R; Garrity E; Valentine V; McCall J; Chow SC; Davis RD; Avery R
Ann Intern Med; 2010 Jun; 152(12):761-9. PubMed ID: 20547904
[TBL] [Abstract][Full Text] [Related]
26. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview.
Grossi P; Mohacsi P; Szabolcs Z; Potena L
Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989
[TBL] [Abstract][Full Text] [Related]
27. Tolerability of up to 200 days of prophylaxis with valganciclovir oral solution and/or film-coated tablets in pediatric kidney transplant recipients at risk of cytomegalovirus disease.
Varela-Fascinetto G; Benchimol C; Reyes-Acevedo R; Genevray M; Bradley D; Ives J; Silva HT
Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27753183
[TBL] [Abstract][Full Text] [Related]
28. Cytomegalovirus prophylaxis with valganciclovir in cytomegalovirus-seropositive kidney-transplant patients.
Wéclawiak H; Kamar N; Mengelle C; Guitard J; Esposito L; Lavayssière L; Cointault O; Ribes D; Rostaing L
J Med Virol; 2008 Jul; 80(7):1228-32. PubMed ID: 18461614
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients.
Park JM; Lake KD; Arenas JD; Fontana RJ
Liver Transpl; 2006 Jan; 12(1):112-6. PubMed ID: 16382458
[TBL] [Abstract][Full Text] [Related]
30. Two strategies for prevention of cytomegalovirus infections after liver transplantation.
Simon P; Sasse M; Laudi S; Petroff D; Bartels M; Kaisers UX; Bercker S
World J Gastroenterol; 2016 Mar; 22(12):3412-7. PubMed ID: 27022223
[TBL] [Abstract][Full Text] [Related]
31. Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients.
Johansson I; Mårtensson G; Nyström U; Nasic S; Andersson R
BMC Infect Dis; 2013 Dec; 13():582. PubMed ID: 24325216
[TBL] [Abstract][Full Text] [Related]
32. Valacyclovir or valganciclovir for cytomegalovirus prophylaxis: A randomized controlled trial in adult and pediatric kidney transplant recipients.
Verghese PS; Evans MD; Hanson A; Hathi J; Chinnakotla S; Matas A; Balfour HH
J Clin Virol; 2024 Jun; 172():105678. PubMed ID: 38688164
[TBL] [Abstract][Full Text] [Related]
33. Cytomegalovirus reactivation and preemptive therapy after liver transplant.
Davoudi S; Kasraianfard A; Ahmadinejad Z; Najafi A; Salimi J; Makarem J; Sohrabpour AA; Jafarian A
Exp Clin Transplant; 2014 Mar; 12 Suppl 1():72-5. PubMed ID: 24635797
[TBL] [Abstract][Full Text] [Related]
34. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy.
Jaksch P; Zweytick B; Kerschner H; Hoda AM; Keplinger M; Lang G; Aigner C; Klepetko W
J Heart Lung Transplant; 2009 Jul; 28(7):670-5. PubMed ID: 19560694
[TBL] [Abstract][Full Text] [Related]
35. Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis.
Kalil AC; Mindru C; Botha JF; Grant WJ; Mercer DF; Olivera MA; McCartan MA; McCashland TM; Langnas AN; Florescu DF
Liver Transpl; 2012 Dec; 18(12):1440-7. PubMed ID: 22887929
[TBL] [Abstract][Full Text] [Related]
36. Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction.
Luan FL
Transplant Proc; 2013; 45(1):175-7. PubMed ID: 23267799
[TBL] [Abstract][Full Text] [Related]
37. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
Boillat Blanco N; Pascual M; Venetz JP; Nseir G; Meylan PR; Manuel O
Transplantation; 2011 Jan; 91(2):251-5. PubMed ID: 21099744
[TBL] [Abstract][Full Text] [Related]
38. The role of secondary cytomegalovirus prophylaxis for kidney and liver transplant recipients.
Sullivan T; Brodginski A; Patel G; Huprikar S
Transplantation; 2015 Apr; 99(4):855-9. PubMed ID: 25208322
[TBL] [Abstract][Full Text] [Related]
39. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
Kuo HT; Ye X; Sampaio MS; Reddy P; Bunnapradist S
Transplantation; 2010 Nov; 90(10):1091-8. PubMed ID: 20885340
[TBL] [Abstract][Full Text] [Related]
40. Early clinical manifestations and laboratory findings before and after treatment of cytomegalovirus infection in kidney transplant patients.
Siddiqui WA; Al Salmi I; Jha A; Pakkyara A; Yasir M; Shaheen FAM
Saudi J Kidney Dis Transpl; 2017; 28(4):774-781. PubMed ID: 28748879
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
